glp 1 mash approval GLP-1 therapies: a new frontier in treatment FDA Approval Expands Novo Nordisk's

The bank said the rapid rise of GLP-1 diabetes and weight loss drugs like Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy could lead to as many as 68 million Americans taking the drug by 2028, or about 20% of the country's population

Setting realistic expectations from the start helps prevent the frustration and disappointment that lead to premature discontinuation

Once signed in, players can set limits, schedule cooling-off periods, and track performance trends via a neat dashboard

However, the FDA also acknowledged that monitoring continues, and the investigation was not considered final